Novavax Secures $400 Million Settlement with Gavi to Resolve COVID-19 Vaccine Contract Dispute
Gavi, Novavax, Settlement and Resettlement
Limited Role for Immuno-Oncology Despite Record Sales at Bavarian Nordic
Bavarian, Biological Markers
ViiV’s Long-Acting Cabenuva Outperforms Daily Oral Therapy in Phase III Study
cabenuva, Daily, Standard of Care, Adherence (attribute), HIV, Participant, daily
AbbVie CEO Gonzalez to Step Down, Robert Michael named Successor in Seamless Transition
Gonzalez, AbbVie’s, company’s, Transition Mutation
Bayer Implements 95% Dividend Cut to Reduce Debt Amid CEO Bill Anderson’s Turnaround Plan
Bayer, Euro currency, Reduced, 95%
FDA Approves Xolair (Omalizumab) for Reducing Severe Outcomes from Multiple Food Allergies
Xolair, United States Food and Drug Administration, omalizumab, Hypersensitivity, Food, Reduced, Severe (severity modifier)
Daiichi Sankyo Invests $1 Billion to Expand German Facility for Precision Cancer Antibody-Drug Conjugates
Daiichi, Sankyo, Antibody-Drug Conjugates
Sanofi and Denali’s ALS Candidate SAR443820 Fails Phase 2 Trial
Amyotrophic Lateral Sclerosis, sanofi, SAR443820, Denali, Collaboration, Denali’s
FDA Approves Amtagvi as the First One-time Cell Therapy for Solid Tumors: A Groundbreaking TIL Immunotherapy for Advanced Melanoma
Amtagvi, Solid Neoplasm, United States Food and Drug Administration, Lymphocytes, Tumor-Infiltrating